Summary
Eli Lilly & Company (LLY) has filed an 8-K report on August 7, 2025, to announce its financial results for the quarter ended June 30, 2025. The report primarily references a press release, filed as Exhibit 99.1, which contains the detailed financial outcomes for the period. Investors should refer to this press release for specifics regarding revenue, earnings, and other key financial metrics. While the 8-K itself does not provide the detailed financial figures, it serves as the official notification mechanism for the release of this information. The filing indicates that the company's financial performance for the second quarter of 2025 has been disclosed. Investors are advised to review the accompanying press release for a comprehensive understanding of Lilly's operational and financial condition as of June 30, 2025, which will inform their investment decisions.
Key Highlights
- 18-K filing by Eli Lilly and Company (LLY) on August 7, 2025, reporting Q2 2025 financial results.
- 2Financial results for the quarter ended June 30, 2025, are announced via an attached press release (Exhibit 99.1).
- 3The 8-K serves as a notification of the financial results release, not a detailed financial statement itself.
- 4Investors need to consult Exhibit 99.1 (the press release) for specific financial performance data.
- 5The filing is categorized under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- 6The press release is dated August 7, 2025.